Wed, Nov 26, 2014, 12:45 PM EST - U.S. Markets close in 3 hrs 15 mins

Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • data_analyst_dude data_analyst_dude Aug 16, 2013 6:56 PM Flag

    Anticipated completion date Aug 2013 on Gemcitabine and TH-302

    to treat first-line metastatic pancreatic adenocarcinoma. Active but not recruiting. Does this mean we won't get an update?

    Phase II

    View of NCT01144455 on 2013_07_16
    ClinicalTrials Identifier: NCT01144455
    Updated: 2013_07_16
    Descriptive Information
    Brief title

    Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
    Official title

    A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
    Brief summary

    Recruitment Information
    Status Active, not recruiting
    Start date 2010-06
    Last follow-up date 2014-01 (Anticipated)
    Primary completion date 2013-08 (Anticipated)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sorry - this is the study that is now in Phase III - the maestro study...

      Based on the encouraging fi ndings from this Phase II study, a Phase III study of TH-302 at 340 mg/m
      2
      combined with gemcitabine was initiated in patients with locally advanced,
      unresectable, and metastatic
      adenocarcinoma of the pancreas

 
THLD
2.965+0.065(+2.24%)12:43 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.